

From Immunology and Autoimmunity to Haematology and back

Virtual | 22-23 May 2026
PRELIMINARY PROGRAMME



Friday, 22 May 2026
(All times in CEST)

14:00 – 14:15 Meeting Opening

Tobias Alexander (DE), Maria Ester Bernardo (IT), Krzysztof Kałwak (PL)

14:15 – 15:30 Session 1: Indications and recommendations

Chairs: TBD and Krzysztof Kałwak (PL)

14:15-14:35 Indications for autologous HCT in Autoimmune Diseases
14:35-14:55 CAR-T for Autoimmune Diseases. Clinical practise recommendations from EBMT
14:55-15:15 Indications for HCT in paediatric autoimmune disorders
15:15-15:30 Session Discussion

Elisa Roldan (UK)
Raffaella Greco (IT)
Juliana Silva (UK)

15:45 – 16:35 Session 2: CAR-T for autoimmune diseases, where do we stand?

Chairs: Mathieu Puyade (FR) and Krzysztof Kałwak (PL)

15:45-16:10 CART-T in adult autoimmune diseases
16:10-16:35 CART-T in paediatric autoimmune diseases

Melanie Hagen (DE)
Marco Becilli (IT)

16:45 – 18:00 Session 3: Gene therapy

Chairs: Maria Ester Bernardo (IT) and Claire Booth (UK)

16:45-17:05 HSC-GT for Inborn Errors of Immunity
17:05-17:25 HSC-GT for Inborn Error of Metabolism
17:25-17:45 Future perspectives of GT strategies, regulatory aspects and accessibility
17:45-18:00 Session Discussion

Claire Booth (UK)
Maria Ester Bernardo (IT)
Alessandro Aiuti (IT)

Saturday, 23 May 2026
(All times in CEST)

09:00 – 10:15 Session 4: Rheumatic and neurological autoimmune diseases

Chairs: Julia Spierings (NL) and Tobias Alexander (DE)

09:00-09:20 CAR-T for Multiple Sclerosis
09:20-09:40 Tailored AHSCT Therapy for Systemic Sclerosis
09:40-10:00 T-cell engagers for systemic sclerosis
10:00-10:15 Session Discussion

Johanna Richter (DE)
Doron Rimar (IL)
Elise Siegert (DE)

10:30 – 11:45 Session 5: Conditioning

Chairs: Fulvio Porta (IT) and Nameer Al-Saadawi (AE)

10:00-10:20 Optimizing serotherapy before HCT
10:20-10:40 Low dose radiotherapy as part of conditioning therapy
10:40-11:20 Pros and cons: busulfan versus treosulfan in non-malignant disorders
11:20-11:45 Session Discussion

Arjan Lankester (NL)
Fulvio Porta (IT)
T: Krzysztof Kałwak(PL)
B: Arjan Lankester (NL)

For further information, please contact education.events@ebmt.org

From Immunology and Autoimmunity to Haematology and back

Virtual | 22-23 May 2026
PRELIMINARY PROGRAMME



Saturday, 23 May 2026 – Continuation
(All times in CEST)

12:00 – 13:00 Session 6: Best Abstracts

Chairs: Claire Horgan (UK) and Rosamaria Nitti (IT)

12:00-12:10	The dramatic impact on viral reactivation and survival in children with IEI using haploidentical HSCT - $\alpha\beta$ T-Cell Depletion and Memory Addback – a pilot study from India	Minakshi Balwani (IN)
12:10-12:20	Haploidentical Hematopoietic Cell Transplantation in Autoimmune Lymphoproliferative Syndrome with a Reduced Toxicity Conditioning Regimen and Modified Post-transplant Cyclophosphamide-based GVHD Prophylaxis	Sayan Sinha Roy (IN)
12:20-12:30	Evaluation of filgrastim (G-CSF) at a dose of 10 mcg/kg/day as a mobilisation protocol combination with cyclophosphamide 2g for patients with Relapsing Remitting Multiple Sclerosis (RRMS) undergoing stem cell harvest—single centre experience	Haili Cui (UK)
12:30-12:40	Hematopoietic stem cell transplantation in children with neutrophil disorders: a single centre experience from South India	Nithya Seshadri (IN)
12:40-12:50	Allogeneic hematopoietic cell transplantation with reduced-toxicity conditioning for X-linked hyper-IgM syndrome	Ryosuke Wakatsuki (JP)
12:50-13:00	Outcome of pediatric allogeneic stem cell transplantation in malignant disease at national stem cell center in Syria	Maged Kherder (SY)

13:30 – 14:45 Session 7: Complications

Chairs: Krzysztof Kałwak (PL) and Giovanna Lucchini (IT)

13:30-13:50	Secondary AD after allo-transplantation haematologic malignancies	Arsène Mekinian (FR)
13:50-14:10	Fertility preservation in CAR-T cell therapy	Giorgio Orofino (IT)
14:10-14:30	HLH after CAR-T	Giovanna Lucchini (IT)
14:30-14:45	Session Discussion	

15:00 – 16:15 Session 8: Expanding the horizon of HCT

Chairs: Raffaella Greco (IT) and Michael Albert (DE)

15:00-15:20	HCT's evolution from classical PIDs to PIRDs	Andrew Gennery (UK)
15:20-15:40	Primary immune deficiency and cancer: chemotherapy and HCT	Kirill Kirgizov (RU)
15:40-16:00	Bringing HCT to children in lower/middle income countries	Lawrence Faulkner (IT)
16:00-16:15	Session Discussion	

16:15 – 16:30 Meeting Closing Remarks

Tobias Alexander (DE), Maria Ester Bernardo (IT), Krzysztof Kałwak (PL)